Oral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual do Centro-Oeste-
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorZiebarth, Jeferson-
Autor(es): dc.creatorda Silva, Letícia Marina-
Autor(es): dc.creatorLorenzett, Ariane Krause Padilha-
Autor(es): dc.creatorFigueiredo, Ingrid Delbone-
Autor(es): dc.creatorCarlstrom, Paulo Fernando-
Autor(es): dc.creatorCardoso, Felipe Nunes-
Autor(es): dc.creatorde Freitas, André Luiz Ferreira-
Autor(es): dc.creatorBaviera, Amanda Martins-
Autor(es): dc.creatorMainardes, Rubiana Mara-
Data de aceite: dc.date.accessioned2025-08-21T21:55:52Z-
Data de disponibilização: dc.date.available2025-08-21T21:55:52Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2024-05-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3390/pharmaceutics16050634-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/296939-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/296939-
Descrição: dc.descriptionLiraglutide (LIRA) is a glucagon-like peptide-1 (GLP-1) receptor agonist renowned for its efficacy in treating type 2 diabetes mellitus (T2DM) and is typically administered via subcutaneous injections. Oral delivery, although more desirable for being painless and potentially enhancing patient adherence, is challenged by the peptide’s low bioavailability and vulnerability to digestive enzymes. This study aimed to develop LIRA-containing zein-based nanoparticles stabilized with eudragit RS100 and chitosan for oral use (Z-ERS-CS/LIRA). These nanoparticles demonstrated a spherical shape, with a mean diameter of 238.6 nm, a polydispersity index of 0.099, a zeta potential of +40.9 mV, and an encapsulation efficiency of 41%. In vitro release studies indicated a prolonged release, with up to 61% of LIRA released over 24 h. Notably, the nanoparticles showed considerable resistance and stability in simulated gastric and intestinal fluids, suggesting protection from pH and enzymatic degradation. Pharmacokinetic analysis revealed that orally administered Z-ERS-CS/LIRA paralleled the pharmacokinetic profile seen with subcutaneously delivered LIRA. Furthermore, in vivo tests on a diabetic rat model showed that Z-ERS-CS/LIRA significantly controlled glucose levels, comparable to the results observed with free LIRA. The findings underscore Z-ERS-CS/LIRA nanoparticles as a promising approach for oral LIRA delivery in T2DM management.-
Descrição: dc.descriptionLaboratory of Nanostructured Formulations Universidade Estadual do Centro-Oeste, Alameda Élio Antonio Dalla Vecchia St., 838, PR-
Descrição: dc.descriptionDepartment of Clinical Analysis School of Pharmaceutical Sciences São Paulo State University, Rodovia Araraquara Jaú, Km 1–s/n, SP-
Descrição: dc.descriptionDepartment of Pharmacy Universidade Estadual do Centro-Oeste, Alameda Élio Antonio Dalla Vecchia St., 838, PR-
Descrição: dc.descriptionDepartment of Clinical Analysis School of Pharmaceutical Sciences São Paulo State University, Rodovia Araraquara Jaú, Km 1–s/n, SP-
Idioma: dc.languageen-
Relação: dc.relationPharmaceutics-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectglucagon-like peptide-1-
Palavras-chave: dc.subjectoral bioavailability-
Palavras-chave: dc.subjecttype 2 diabetes mellitus-
Palavras-chave: dc.subjectzein nanoparticles-
Título: dc.titleOral Delivery of Liraglutide-Loaded Zein/Eudragit-Chitosan Nanoparticles Provides Pharmacokinetic and Glycemic Outcomes Comparable to Its Subcutaneous Injection in Rats-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.